Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Gram-negative bacterial outer membrane lipopolysaccharide (LPS) and cytoplasmic membrane phospholipids are essential structural components that define the cell envelope of Gram-negative bacteria [1]. LPS is a complex glycolipid found in the outer leaflet of the outer membrane, where it acts as a potent endotoxin and a critical permeability barrier against toxic molecules, including many antibiotics [3]. This structure is stabilized by divalent cations like magnesium and calcium that bridge the negatively charged phosphate groups of the lipid A moiety [6]. The cytoplasmic membrane, located beneath the peptidoglycan layer, consists of a phospholipid bilayer that regulates the transport of solutes and maintains the cell's energetic state [7]. Polymyxin antibiotics, such as polymyxin B and colistin, specifically target this system by displacing the stabilizing cations from LPS, leading to outer membrane disruption [8]. Following this initial interaction, the drugs insert into the cytoplasmic membrane phospholipids, creating pores that cause the leakage of essential intracellular contents and rapid bacterial death [2, 5]. Because of their unique mechanism, these components are vital targets for treating multidrug-resistant Gram-negative infections, although their use is often limited by significant side effects like nephrotoxicity [8].
Polymyxins act by binding to the lipid A portion of lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria, displacing divalent cations (Mg2+ and Ca2+) that normally stabilize the LPS layer. This displacement destabilizes the outer membrane, allowing the drug to penetrate the periplasm and reach the cytoplasmic membrane. There, the drug inserts into the phospholipid bilayer, causing pore formation, leakage of intracellular contents, and ultimately bacterial cell death.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gram-negative bacterial outer membrane lipopolysaccharide and cytoplasmic membrane phospholipids (LPS/Phospholipids).